Complex Drug Network of Danshen Chuanxiongqin Injection(丹参川芎嗪注射液)Treatment for Liver Insufficiency

Objective:To study the characteristics and rules of medication regimen for patients with Liver insufficiency treated with Danshen Chuanxiongqin Injection.Methods:The inpatient information of Danshen Chuanxiongqin Injection with Liver insufficiency was extracted from the hospital information system(HIS)database of 12 Class A tertiary hospitals in China.Tabu search(TS)algorithm was used for obtaining sub-network and density matrix,matrix method or sociogram was used to show the relationship between different sub-networks,searching for core prescriptions of treatment options,associations and strong correlations between multiple drugs.Results:The treatment plan of integrated Chinese and Western medicine of Danshen Chuanxiongqin Injection on Liver insufficiency mainly includes of cerebrovascular disease in acute stress state:Danshen Chuanxiongqin Injection combined with alanyl glutamine;Treatment of acute ischemic cardiovascular and cerebrovascular diseases:Danshen Chuanxiongqin Injection combined with Levocarnitine+acetylsalicylic acid+inosine tablets+brain protein hydrolysate+glutathione+furosemide+Magnesium aspartate+metoprolol;Treatment of ischemic cardiomyopathy angina pectoris with traditional Chinese medicine:Danshen Chuanxiongqin Injection combined with Shexiang Baoxin Pills+Suxiao Jiuxin Pills+Fufang Danshen Drops;Treatment of ischemic cardiovascular disease complicated with Liver insufficiency with traditional Chinese medicine:Danshen Chuanxiongqin Injection combined with Dazhu Hongjingtian Capsule+Shuganning Injection.Conclusion:For Danshen Chuanxiongqin Injection in patients with Liver insufficiency,on the basis of conventional symptomatic treatment,attention should be paid to the liver function of the patients,integrated therapy can be more selective,can improve the efficacy in different degrees.Danshen Chuanxiongqin Injection combination scheme of Liver insufficiency in routine clinical diagnosis and treatment provides a more effective reference for clinical individualized treatment.

Current strategies to induce liver remnant hypertrophy before major liver resection

Hepatic resection is the gold standard for patients affected by primary or metastatic liver tumors but is hampered by the risk of post-hepatectomy liver failure.Despite recent impro-vements,liver surgery still requires excellent clinical judgement in selecting patients for surgery and,above all,efficient pre-operative strategies to provide adequate future liver remnant.The aim of this article is to review the literature on the rational,the preliminary assessment,the advantages as well as the limits of each existing technique for preparing the liver for major hepatectomy.

Long-term results of liver transplantation for over 60 years old patients with hepatitis B virus-related end-stage liver disease

BACKGROUND： Hepatitis B virus（HBV）-related end-stage liver disease is the leading indication for liver transplantation in China, but long-term results of liver transplantation in patients aged over 60 years are not clear. The present study was to reveal the natural history of liver recipients with hepatitis B older than60 years.METHODS： The recipients who had received liver transplantation between December 2003 and December 2005 were divided into two groups： those equal or older than 60 years（older group,n60） and those younger than 60 years（younger group, n305）.Risk factors for poor long-term outcome in patients aged over 60 years were also analyzed.RESULTS： Except for age and preexisting chronic disease（P0.05）,no significant differences were observed in perioperative characteristics between the two groups. There was also no significant difference in HBV and hepatocellular carcinoma recurrence（P0.05）. The actuarial 1-, 3-, 5- and 8-year survival rates were 81.6%, 71.6%, 66.7% and 63.3% respectively for the older group vs 84.9%, 77.7%, 70.8% and 65.6% for the younger group（P0.05）. Multivariate analyses showed that pre-liver transplant renal insufficiency was a risk factor for poor outcome in the older group（odds ratio=3.615, P0.014）.CONCLUSIONS： Liver transplantation is safe and feasible for patients with HBV-related end-stage liver disease aged over 60years. Older patients with renal insufficiency should undergo transplantation earlier than younger patients.